Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court’s decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.
Charges still not finalised in groundbreaking ANZ criminal cartel case
Liquidators settle case over collapse of funder Centaur Litigation
Optus hit with $25k criminal fine over lax political donation disclosures
ANZ mulled repricing controversial $2.5B capital raising, ASIC claims
ANZ Bank executives briefly considered relaunching and repricing a botched $2.5 billion equity capital raising at the heart of two groundbreaking enforcement actions, and the decision by the share placement’s underwriters to instead pick up a $790 million shortfall deprived investors of lower priced shares, a court has been told.